Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMDA Antagonists in Bipolar Depression

Trial Profile

NMDA Antagonists in Bipolar Depression

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Cycloserine (Primary) ; Ketamine (Primary) ; Lurasidone; Olanzapine/fluoxetine; Quetiapine
  • Indications Bipolar depression; Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 25 Apr 2016 Safety and tolerability of ketamine and d-cycloserine removed from primary endpoint ; hence trial focus changed from TU + AR to TU.
    • 25 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top